The HIV vaccine saga by Smith, Kendall A
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Medical Immunology
Open Access Commentary
The HIV vaccine saga
Kendall A Smith*
Address: The Division of Immunology, Department of Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA
Email: Kendall A Smith* - kasmith@med.cornell.edu
* Corresponding author    
Abstract
The development of a vaccine that can prevent infection by the Human immunodeficiency virus or
prevent the Acquired Immunodeficiency Syndrome has remained elusive despite 20 years of
scientific effort. This "Commentary" analyzes the reasons that the development of a vaccine has
been so difficult, and proposes a plan to work towards an immunological approach to investigate
the best vaccine candidates in the first world in individuals who are already infected, before taking
the most promising vaccines to the developing world to attempt to prevent infection and disease.
                                  SAGA: (Old Norse) "a long, continued heroic story that is action-packed,
but not especially romantic, and that is historical or legendary or both".                             
Introduction
In 1984, Margaret Heckler, then Secretary of Health, Edu-
cation and Welfare, called a press conference and an-
nounced that Robert Gallo of the National Cancer
Institute had discovered the virus responsible for causing
the Acquired Immunodeficiency Syndrome (AIDS). Gallo
then predicted that a vaccine for this dread affliction
would soon be in hand, certainly within two years. How-
ever, years passed, until in 1997 President Clinton de-
clared, "an HIV vaccine would be developed in a decade's
time". Subsequently, in his State of the Union Address,
2003, President Bush stated that he is now going to ask
Congress to appropriate $15 billion to combat the spread-
ing HIV epidemic in Africa and the Caribbean, and an
AIDS vaccine still is nowhere in sight.
Twenty years after the discovery of the AIDS virus, now
known as the Human Immunodeficiency Virus (HIV), we
know that HIV was actually first isolated and reported in
1983 by a team from the Pasteur Institute lead by Luc
Montagnier, and that Gallo's group had simply re-isolated
the same virus that the French team had sent to them a
year earlier, thereby confirming the veracity of the original
isolate and solidifying the putative cause of AIDS as due
to a new retrovirus [1,2]. Moreover, despite a huge
amount of money directed to basic and clinical science
since that time, a vaccine that can prevent infection by
HIV remains elusive. If this has not been a "saga" there
never was one. But why has the development of an HIV
vaccine been so difficult, and is there no end in sight?
Some of the answers to these simple questions reside in
the history of immunology, which was detailed by my ed-
itorial entitled "Medical Immunology: A New Journal for
a New Subspecialty" [3]. We really have not understood
what actually constitutes a successful vaccine, despite the
more than two centuries that have elapsed since Sir Ed-
ward Jenner described the first effective vaccine for small-
pox virus in 1798 [4]. Consequently, all of the vaccines
currently in use were developed empirically, and only
within the past 50 years, without a comprehensive under-
standing as to how the immune system functions.
Now we are confronted with the worst pandemic in histo-
ry, a pandemic that threatens to unravel societies around
the world, just at the time that we have all become inter-
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dependent in a "global economy". Accordingly, the search
for an effective HIV vaccine is perhaps the most important
scientific challenge of our generation, if not the most cru-
cial ever in the history of science. Therefore, at this junc-
ture it is imperative to detail the progress and the
prospects in the quest.
Discussion
Subunit Vaccines and Neutralizing Antibodies
Initially, it was thought that a subunit vaccine, construct-
ed from the viral envelope protein, could be rapidly and
efficiently developed using the modern techniques availa-
ble through genetic engineering. It was thought that im-
munization with the viral envelope glycoprotein, gp120,
should generate neutralizing antibodies that would pre-
vent infection, thereby yielding protective immunity. Of
course, this was the traditional approach to vaccine devel-
opment from the '50s. Successful immunization was test-
ed by monitoring for serum neutralization of viral
infectivity in vitro. However, unbeknownst to these earliest
AIDS vaccine investigators, it turns out that HIV had al-
ready evolved very complex ways to evade antibodies that
bind to the distinct areas of the viral envelope molecules
where they interact with the cell surface virus receptors.
Therefore, neutralizing antibodies are very difficult to gen-
erate, either after natural infection or immunization.
The viral envelope molecules are heavily glycosylated, and
the large carbohydrate molecules serve to mask potential
protein epitopes, as well as hinder antibody binding even
if such antibodies are generated. In addition, the envelope
molecules are expressed as trimers, which very rapidly un-
dergo marked conformational changes upon contact with
the viral cell surface receptors, CD4 and CCR5/CXCR4 [5].
These conformational changes occur so rapidly that the
transition state is only open to immune recognition brief-
ly. Consequently, investigators are now trying to generate
stable trimeric gp120/gp41 molecules that can be used as
immunogens, which will stimulate antibodies that can
compete for the binding sites on the cell surface receptor
molecules. Although a great deal of progress has been
made [6,7], this "holy grail" of HIV immunology still is
not within reach.
Antigen Processing and Presentation to T Lymphocytes (T 
cells)
At the time that HIV was discovered in 1983 [8], immu-
nologists were just beginning to unravel the complex
processes of antigen processing and presentation, and to
realize that there are two separate intracellular pathways
that regulate antigen recognition by T cells (for review see
[3]). The understanding that there is an "endogenous
pathway" and an "exogenous pathway" of antigen
processing and presentation actually required another
decade. Therefore, only within the past several years has it
become apparent that intracellular infections, especially
those due to viruses, require that the viral proteins be syn-
thesized inside the cell and then processed into short pep-
tides and loaded onto HLA molecules encoded by the
Major Histocompatibility Complex (MHC) Class I genes.
Thus, if gp120 or other viral proteins are administered as
vaccines, they will not be processed by this pathway, and
thus will not activate CD8+ T cells, which are the cells that
are primarily responsible for combating intracellular in-
fections.
Recombinant proteins administered as vaccines are proc-
essed and presented by the "exogenous pathway" by anti-
gen presenting cells (APCs). This pathway loads antigenic
peptides onto HLA molecules encoded by the Class II
MHC gene region and ultimately activate CD4+ "helper"
T cells. These cells then can "help" the generation of anti-
bodies by B cells and plasma cells, but as noted above, the
viral envelope has already thwarted this avenue of de-
fense. Accordingly, the "quick fix" envisioned by early vi-
rologists was doomed from the beginning.
Cytokines and the Cell-Mediated Immune (CMI) Response
1983 was also the year that interleukin 2 (IL2) became the
first interleukin molecule to be purified to homogeneity
[9], cloned and sequenced [10]. Soon thereafter it was
demonstrated that the rapid T cell proliferation that oc-
curs in vitro after activation with mitogens and antigens is
dependent upon the production and action of IL2 by the
antigen-selected T cells [11]. However, it wasn't until 1998
that it was possible to demonstrate by in vivo experiments
that viral antigen-activated T cells undergo a similar rapid
and massive proliferative expansion [12–15]. As well, de-
tailed experiments only within the past few years have re-
vealed the crucial role of antiviral cytokines secreted by
CD8+ CTL in curtailing viral replication, such as interfer-
on-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-
α), as a result of advances in flow cytometry and the detec-
tion of intracellular cytokines using monoclonal antibod-
ies [16,17].
Successful Vaccines Against Viruses
But what about all the vaccines against all of the viruses
that cause the acute infectious diseases of childhood, e.g.
poliovirus, measles virus, mumps virus, Rubella virus,
chicken pox virus etc., etc.? All of these vaccines were de-
veloped empirically in the '50s and '60s before CMI was
known about, and almost all of the successful vaccines
that have been generated are live attenuated viruses. The
key words here are live and attenuated. Since these viruses
are alive, they establish an infection in the cells of the vac-
cinee. Consequently, the viruses replicate inside the host's
cells. This serves to markedly amplify the antigen "dose".
As well, while the viruses replicate, their proteins are proc-
essed by the endogenous pathway and presented on theMedical Immunology 2003, 2 http://www.medimmunol.com/content/2/1/1
Page 3 of 7
(page number not for citation purposes)
cell surface bound to Class I HLA molecules, thereby acti-
vating CD8+ cytolytic T cells (CTL).
Simultaneously, because the infected cells produce ma-
ture virions that exit the cells, these virions are opsonized
by plasma proteins, and then taken up by phagocytic an-
tigen presenting cells (APCs, macrophages and dendritic
cells), which digest the virions, process their proteins to
short peptides, and then load them onto HLA Class II
molecules. These viral peptide-Class II HLA complexes ex-
pressed on the surface of the APCs then activate CD4+ T
cells. CD4+ T cells are professional "helpers", and they
function to promote both antibody formation by B cells/
plasma cells as well as to promote the proliferation and
function of CTLs. They do so by expressing "helper mole-
cules" on their cell surface, and as well, as secreted helper
molecules (cytokines or interleukins). For example, it
turns out, that during an immune response ~80% of the
IL2 produced is made by CD4+ helper T cells, whereas
CD8+ T cells make only ~20% of the IL2 produced [18].
Therefore, the magnitude of expansion of the number of
virus-reactive CD8+ CTLs is highly dependent on CD4+
helper T cells.
The other key word is attenuate. Early on, Albert Sabin
found that he could attenuate poliovirus by passaging the
virus multiple times in cell cultures. Now we know that
this process allowed for the accumulation of many muta-
tions in the viral genome. However, because the selection
in vitro was governed by viral replication, mutant viruses
were derived that had retained their capacity to replicate,
a desirable characteristic, but somehow mysteriously they
lost their capacity to cause disease, or virulence. Therefore
upon inoculation, these attenuated vaccines infect host
cells and replicate transiently, thereby amplifying the
amounts of viral antigens produced, and thus stimulating
a very strong cell-mediated immune (CMI) response. This
CMI recognizes and responds to the local infection at the
site of inoculation, eradicating the viral vaccine, and leav-
ing behind an expanded population of memory CD4+
and CD8+ T cells that confer life-long protective immuni-
ty.
There is one risk to attenuated viral vaccines. If the host is
immunocompromised, there is a danger that the host im-
mune response cannot eradicate the local viral vaccine in-
fection. This can result in disseminated "vaccinosis", and
disease caused by a systemic infection of the virus com-
prising the vaccine. The best example of this danger occurs
after vaccination for smallpox virus with the cowpox vi-
rus, termed vaccinia, which was first described by Jenner
[4]. A disseminated vaccinia infection can lead to en-
cephalitis and death. This has recently become an issue, as
the Bush Administration has proposed to vaccinate
~500,000 health care workers as a precaution against a
possible bio-terrorist attack. Since the cowpox vaccine rep-
licates transiently in a healthy vaccinee, these individuals
are contagious for ~2–3 weeks. Accordingly, with ~1 mil-
lion HIV-infected individuals in the U.S., there is a signif-
icant risk of transmission of vaccinia from the vaccinated
health care workers to the "at-risk" population of HIV+ in-
dividuals.
Accordingly, because of safety concerns live attenuated
HIV vaccines have been ruled out. In addition, all of the
HIV vaccines under development have been chosen so
that the viruses used as "vectors" are crippled and are rep-
lication defective. Thus, "naked" DNA vaccines derived
from bacterial viruses (plasmids) cannot replicate in hu-
man cells. As well, vaccines produced in viral vectors de-
rived from canarypox virus, fowlpox virus, adenovirus,
alpha virus etc. have been purposely chosen because these
viruses are replication-defective in human cells. Conse-
quently, one advantage of using live viruses as vectors for
vaccines is lost. The vaccine virus cannot replicate in the
host tissues, even transiently, so that the antigen dose is
orders of magnitude less than can be achieved by a viral
vaccine that can replicate.
The caveat is that the attenuated, live viral vectors can still
infect host cells, so that they deliver the virally-encoded
genes into the cell, and the expressed viral gene products
are processed into short peptides and presented on the
cell surface bound to HLA Class I molecules that can stim-
ulate the recognition and response of CD8+ CTLs. Even
so, with the loss of vaccine replication, all of the current
HIV vaccines in development are relatively weak immu-
nogens as determined by measurements of both humoral
and CMI. They are relatively weak vaccines because they
do not replicate so that the antigen dose is limited. Also
they are weak immunogens because they do not produce
mature virions that can be taken up by APCs. Therefore,
viral peptides are not processed via the "exogenous" Class
II HLA pathway, activating CD4+ T helper cells. Thus,
without help the CD8+ T cell proliferative response is
blunted and meager, as is the humoral antibody response.
Protection From Disease instead of Prevention of Infection
Traditionally, vaccine-induced generation of high titers of
neutralizing antibodies was found to prevent infection
upon exposure to the wild-type virus in the field, and this
is the way new vaccines are traditionally tested. The vac-
cine doses and regimens are first tested in normal volun-
teers for their capacity to invoke high titers of neutralizing
antibodies. Then, the vaccine and placebo are introduced
into a population where the incidence of infection is high,
and the frequencies of infections are compared in the vac-
cinated group vs. the placebo control group. This ap-
proach requires a reasonably high incidence of infection
in the endogenous population, and a reasonable rate ofMedical Immunology 2003, 2 http://www.medimmunol.com/content/2/1/1
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infection, so that the trial can be conducted in a reasona-
ble time frame. However, even in the best of circumstanc-
es, usually several thousand volunteers and several years
are required to acquire definitive data as to whether a vac-
cine will work, and how well it works, i.e. whether it con-
fers complete protection from infection, or only partially
effective, affording protection for a fraction of vaccinees
compared with the incidence in the placebo control
group.
If a vaccine fails to prevent infection, it can still be quite
effective if it can be shown to prevent the disease caused
by the wild-type virus. Actually, for most of the present
vaccines, tests for the persistence of viral genome in the
host were not available when the original vaccines were
developed, so that whether the vaccine prevents infection
or protects against development of disease remains un-
known.
The Simian Immunodeficiency Virus (SIV) Model
SIV infection of Rhesus macaques has been found to result
in an immunodeficiency syndrome very similar to the
AIDS caused by HIV infection of humans. In hopes of cre-
ating an animal model that would mimic the human in-
fection, Reiman and Letvin and their co-workers
generated chimeric simian/human immunodeficiency vi-
ruses (SHIV) [19]. Viruses composed of SIVmac239 ex-
pressing HIV-1 env and associated auxiliary HIV-1 genes
tat, vpu, and rev, is designated SHIV89.6P. One of the ma-
jor differences between the infections of macaques by
SHIV89.6P vs. HIV infections of humans is the rate of de-
velopment of AIDS, which occurs after just a few months
in the SHIV-infected macaque, compared with several
years in HIV-infected humans. Therefore, the SHIV-in-
duced disease is an acute infection compared with the
chronic infection caused by HIV. From the standpoint of
a vaccine model, this aspect of SIV infection works to the
advantage of the investigator. SHIV vaccine clinical trials
can be conducted over a much shorter time interval than
would be the case if the macaque infection model had a
similar time frame as the human infection. In addition, an
obvious advantage to the SHIV model is that experiments
can be conducted where all of the vaccinated animals can
be challenged with wild-type virus simultaneously, and
virologic and immunologic parameters can be monitored
carefully.
Using this model, Dan Barouch and Norm Letvin and
their co-workers have pioneered the SHIV model to test
vaccines [20,21]. In several recent reports they have found
that it is possible to protect Rhesus macaques from the de-
velopment of AIDS, but it has not yet been possible to
demonstrate that vaccination can prevent infection by
SHIV. In experiments testing naked DNA vaccines com-
prised of the envelope from HIV and the SIV Group-spe-
cific Antigen Genes (gag) they found that when given
alone, the naked DNA vaccine was a weak immunogen. By
comparison, there was a readily detectable CMI response
when IL2 was administered together with the first two
doses of vaccine in the form of a chimeric IL2-Ig protein,
which functions to prolong it's plasma half-life, or as the
gene encoding the IL2-Ig chimera [20]. As well, after chal-
lenge with SHIV89.6P, all of the animals that received the
control, empty vector, or naked DNA vaccines alone, de-
veloped persistent viremia, falling CD4+ T cell counts,
and eventually succumbed to AIDS. By comparison, after
challenging the animals that received the DNA vaccines
given together with IL2-Ig, there were potent secondary
CTL responses, the CD4+ T cell concentrations remained
stable and normal, in vitro CD4+ T cell SHIV-specific pro-
liferative responses were maintained, the peak plasma
SHIV concentrations were ~10-fold lower than in animals
that received either no vaccine or naked DNA vaccine
alone, and the eventual viral "set points" were < 1,000
copies/mL. Even more notable, none of the 8 animals that
received the DNA vaccine + IL2-Ig had evidence of clinical
disease by day 140 (5 months) after viral challenge, while
half of the controls had died.
These experiments thus provided "proof of concept" that
it is possible to boost immune recognition and reactivity
to SHIV infection by immunization with naked DNA vac-
cines, and furthermore they pointed the way to the use of
cytokines as adjuvants, to boost the poorly immunogenic
non-replicative vaccines. Subsequently, Shiver and co-
workers reported success with naked DNA vaccines com-
bined with modified vaccinia Ankara (MVA) virus (which
is replication incompetent in mammalian cells) and a rep-
lication incompetent adenovirus type 5 (Ad5) vector [22].
These investigators did not use IL2 or other cytokines as
adjuvants, but they also did not achieve the same degree
of immune reactivity as reported by the Barouch team.
More recently, Barouch and co-workers reported that one
of the 8 animals that were virus and disease-free 5 months
after virus challenge had subsequently suffered a viral re-
lapse at week 24 and succumbed to AIDS at week 52 [23].
Moreover, they were able to detect that one "immunodo-
minant" CTL epitope had undergone a mutation, thereby
suggesting that the immunosurveillance is ongoing in
these vaccinated and challenged animals, and that escape
from immune recognition is a danger. Even so, 7/8 ani-
mals remain virus- and disease-free > 2 years after virus
challenge.
Very recently, Willey and co-workers reported on experi-
ments using the SHIV model and recombinant vaccinia vi-
rus plus chemically inactivated SIV and HIV viral particles
as vaccines [24]. Macaques were immunized with the re-
combinant vaccinia vaccines on weeks 0 and 8, and thenMedical Immunology 2003, 2 http://www.medimmunol.com/content/2/1/1
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followed with injections of the viral particles on weeks 20
and 28. Following virus challenge on week 46, all control
animals experienced a rapid and complete loss of CD4+ T
cells, sustained high plasma virus concentrations, and de-
veloped AIDS by 17 to 21 weeks. By comparison, al-
though all the vaccinated monkeys became infected, they
displayed reduced peak viremia, had no significant loss of
CD4+ T cells, and have remained healthy for more than
15 months post infection. Even so, these animals still
have detectable viremia, albeit at low concentrations,
~1,000 mol/mL.
All of these experiments in the experimental macaque
model system point towards the capacity of the host to
contain the virus after infection, and they indicate that it
is possible to boost immune reactivity prophylactically
with various vaccines and adjuvants. However, the SHIV-
macaque model is still only a model [25], so that these
principles must be transferred to the human, and then
tested as rapidly as possible to discern how best to stimu-
late immunity to HIV.
Testing Vaccine Candidates in Humans: Ethical and Prac-
tical Issues
Moving from monkeys to man is a big step. Recently, an
article in The New Yorker entitled "The Vaccine" very aptly
posed the question, "Has the race to save Africa from AIDS
put Western science at odds with Western ethics?" [26]. This
article details the difficulties in testing a vaccine candidate
for efficacy in the third world, where cultural beliefs and
superstitions are compounded by political instability and
the lack of a medical infrastructure. The article quotes No-
bel Laureate and head of the AIDS Vaccine Initiative, Dav-
id Baltimore, who has said repeatedly that this battle will
take many years, a lot of money and many people.
The problem of convincing an uneducated and suspicious
populace to participate in an experiment to test an un-
proven vaccine for the capacity to prevent HIV infection is
underscored by a statement from one African leader who
said that it was easier to convince people of his country to
submit to poliovirus vaccination, because it had already
been shown to be efficacious in the "first world".
At this point, HIV vaccines have been tested in normal hu-
man volunteers for more than a decade, and there are
plans to begin large-scale prophylactic vaccine trials soon.
For example, Aventis Pasteur has developed a candidate
vaccine from canarypox virus that they plan to test in a
placebo-controlled trial in Thailand on 16,000 normal,
HIV-negative volunteers. They estimate that the trial will
proceed for at least 4 years before any data will become
available as to the efficacy of their vaccine [27].
An additional difficulty of testing vaccines vs. testing anti-
viral drugs relates to the nature of the immune system and
immunologic memory. An individual can participate in
multiple successive trials testing antivirals after a suitable
washout period to ensure that there is no longer any drug
remaining before administering a new agent. As well, be-
cause the antiviral drugs target the virus, instead of the
host, there is less concern that a prior exposure will have
altered the host. However, a vaccine targets the immune
system, and the immune system remembers past expo-
sures. Thus, an individual can ideally only volunteer for
one vaccine trial. If the individuals of a community have
already participated in a vaccine trial, their immune sys-
tems have been primed to the antigens contained in the
vaccine and they will have an anamnestic response rather
than a primary response to a new vaccine that contains the
same or similar antigens.
Finally, ethicists are concerned that the volunteers in a
vaccine trial in the third world should be treated identical-
ly as would volunteers from the first world. Thus, there is
a debate as to whether volunteers in a vaccine trial who re-
ceive placebo, and who subsequently become infected
with HIV be offered the expensive, life-saving antiviral
medications that are available in the first world, but not
common practice in their society. Who should pay for
these drugs? As well, is it ethical to administer these drugs
to the vaccine volunteers but not to individuals of the so-
ciety who have not volunteered for the trial?
The Solution: Test Candidate Vaccines First in the "First" 
World in HIV+ Volunteers
Conventional wisdom has maintained that once HIV in-
fection becomes chronic, i.e. once the virus invades the
host and establishes itself in susceptible CD4+ T cells, the
immune system is irrevocably compromised [28]. In favor
of this viewpoint is the fact that antiviral drugs are not cur-
ative. Thus, even though antivirals can reduce plasma HIV
concentrations to undetectable levels for months and
even years, if the drugs are discontinued, viremia recurs
within a few weeks, and the immune system still cannot
prevent the relapse [29], even though the antivirals have
reduced the total viral burden to a tiny fraction of cells, ~1
infected cell per million CD4+ T cells [30].
Against this conventional wisdom are our studies in
which we treated chronically infected subjects with antivi-
rals and IL2 for at least 3 months, following which we dis-
continued the antivirals, continued the IL2
administration and then monitored the plasma HIV con-
centration and the concentration of circulating lym-
phocytes [31] (and unpublished data). Thus far, in 15
subjects we have found a characteristic relapse of viremia
within ~2 1/2 weeks, then a rapid increase in HIV concen-
tration for ~2 weeks (mean doubling time 1.6 days) to aMedical Immunology 2003, 2 http://www.medimmunol.com/content/2/1/1
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peak viral concentration of ~250,000 HIV RNA mol/mL.
Subsequently, the circulating CD8+ T cell concentration
doubled and the plasma HIV concentration declined ~10-
fold to a mean "trough" or viral "set point" concentration
of ~25,000 HIV RNA mol/mL. Moreover, the rate of de-
cline of the plasma virus concentration correlated with the
magnitude of the increase in the CD8+ T cell concentra-
tion.
These findings are reminiscent of the changes in viral and
lymphocyte dynamics that occur after a primary infection.
However, they are more consistent with an anamnestic
immune response, which would be expected of a
"primed" host. Thus, the rate of viral increase is ~4–5-fold
slower than in a primary infection, and the peak viral con-
centration is ~100-fold lower than in a primary infection
[32]. Moreover, the rate of decline of the plasma virus
concentration, which has been attributed to CD8+ T cells
in the macaque model system, is just as rapid as observed
after the administration of antivirals (i.e. t1/2 = 2–3 days)
[33,34].
Given these data, one can readily see how the viral and
lymphocyte dynamics after a brief 8–12 week discontinu-
ation of antivirals can be used to test the capacity of the
immune system to recognize and respond to each individ-
ual's endogenous virus. Accordingly, we have termed this
treatment interruption as a "Diagnostic Treatment Inter-
ruption" (DTI) to designate that it is not a therapeutic ma-
nipulation as a "Structured Treatment Interruption" (STI)
has come to denote. Moreover, a DTI is diagnostic of the
capacity of the immune system to recognize, react and
control the virus in the absence of the suppressive antivi-
ral drugs [18,35].
The advantage of a DTI for a clinical trial design to test
HIV vaccines is obvious. The determination of the plasma
HIV concentration is now a very sensitive, reproducible
and accurate assay. In addition, because the viral relapse
occurs so rapidly, within ~2–3 weeks, the outcome of the
vaccination can be determined in a very short time inter-
val. In essence, this clinical trial design is similar to the de-
sign used in cancer therapy, where chemotherapy is given
until the cancer is no longer evident, and then a relapse
rate of the return of detectable tumors is monitored after
the chemotherapy is withdrawn. The additional advan-
tage is that the viral load assay is analogous to monitoring
a biochemical tumor maker such as the PSA test is used to
diagnose the relapse of prostate cancer, without waiting
for the return of grossly detectable tumor.
The other obvious advantage of the use of a DTI to test the
efficacy of HIV vaccines and immune-based therapies
(IBTs) is that it tests directly the antiviral capacity of the im-
mune system, and does not rely on the use of assays of the
immune system function that may, or may not, correlate
with an antiviral response. For example, measurements of
lymphocyte proliferation assays or cytotoxicity assays, or
ELISPOTs or flow cytometry of antigen-activated cells
only give a measurement of the antiviral potential of the
immune system and do not actually measure its antiviral
capacity.
Accordingly, it is possible to test the various vaccines in
development, as well the various doses and regimens,
with and without cytokines in the "first" world, where we
have available all the infrastructures of clinical medicine
and basic science, as well as an educated and motivated
population of volunteers. If a particular vaccine, dose and
regimen tests superior in therapeutic vaccine trials, then
this formula should be the one taken to prophylactic tests
in the "third" world.
One last aspect of vaccine testing to discuss is the tradition
of a placebo control. In cancer chemotherapy trials, a pla-
cebo control is no longer used or considered to be ethical.
Thus, "standard therapy" serves as the control group, with
which an experimental group is compared. Accordingly,
before testing new vaccines in the third world, at least two
promising vaccines, doses and regimens should first be
identified in the first world in therapeutic trials, and then
compared with one another in the third world in prophy-
lactic trials. If one vaccine and regimen is found superior
to the other, it should then be used as the "standard vac-
cine" for comparison with an experimental vaccine in the
next trial. This approach should make the idea of volun-
teering for a vaccine trial in the third world much more
palatable, and therefore decidedly more easily accom-
plished by first and third world scientists and physicians,
working together.
Conclusions
Given the understanding of how the immune system
functions, combined with the ability to rapidly and defin-
itively test therapeutic vaccines in HIV+ volunteers, a ra-
tional and successful approach to testing therapeutic and
prophylactic HIV vaccines is now within reach. However,
the scientific, medical and HIV-infected communities of
the first world must mobilize to perform the necessary
crucial clinical research before vaccines and immuno-
therapies can be applied effectively worldwide as rapidly
as possible.
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